Few commercial real estate sectors have experienced the swings that life sciences have seen over the past few years. A surge of venture capital, heightened attention to biomedical research during the pandemic and expectations for continued rapid growth sent developers racing to add laboratory and research space in established clusters and emerging markets alike.
The environment today looks very different. Funding is more selective, tenants are scrutinizing their space needs and the development pipeline has slowed considerably. For commercial real estate owners and brokers, that can look like a sector retreating from the extraordinary growth of the early 2020s.
A more useful way to view the current environment may be as a transition from expansion to maturation.
Capital Is Available, But It Is More Selective
The ecosystem supporting life sciences real estate remains substantial. The National Institutes of Health awarded $35.3 billion through competing and noncompeting grants in fiscal 2025, while total NIH program-level funding for fiscal 2026 is $47.5 billion. The U.S. Food and Drug Administration, meanwhile, approved 46 novel drugs in 2025, following 50 in 2024.
Venture funding provides another illustration of the shift.
According to the National Venture Capital Association’s 2026 Yearbook, life sciences companies attracted $37.3 billion of venture investment in 2025. That was up from $35.7 billion in 2024 and $31 billion in 2023, but still well below the extraordinary $54.7 billion invested in 2021. The number of deals tells an equally important story. Approximately 1,908 life sciences venture deals closed in 2025, compared with 2,694 at the 2021 peak.
While capital has not disappeared, it appears to be reaching fewer companies.
PitchBook and NVCA data show that the median life sciences venture deal reached $6.4 million in 2025, up from $5.1 million a year earlier, while the average deal increased from $23 million to $25.8 million. Fewer transactions alongside larger typical financings suggest investors are still willing to put money to work, but are being more discriminating about which companies receive it.
That has implications for real estate. During periods of abundant startup capital, landlords could benefit from a large population of young companies rapidly adding employees and laboratory space. A more selective funding environment favors companies with clearer paths to clinical milestones, commercialization or additional financing. Those companies may still expand, but there is less incentive to commit to space years ahead of when it will actually be needed.
The Tenant Has Changed, Too
Life science tenant preferences are also shifting post-pandemic. One indication can be found in employment. Bureau of Labor Statistics data show that production and nonsupervisory employment in physical, engineering and life sciences research and development declined from approximately 653,000 in January 2025 to 643,000 by December. While the category is broader than life sciences alone, the decline illustrates a different hiring environment from the rapid expansion that helped drive demand earlier in the decade.
For real estate decision-making, slower headcount growth changes the calculation. A growing company has less reason to lease substantially more space than it currently requires on the assumption that another funding round and a hiring surge will quickly fill it. Tenants have greater incentive to focus on efficient layouts, flexible expansion options and buildings capable of supporting changing research requirements.
Building specifications matter more in that environment. Reliable power, ventilation and mechanical systems, appropriate floor loads and ceiling heights, backup systems, loading and material handling capabilities, proximity to research institutions and talent, and the ability to modify space as research advances can all affect whether a building works for a particular occupier.
Laboratory space is also far less interchangeable than conventional office space. Two buildings may both offer wet labs but have very different utility for prospective tenants. Research programs can require different levels of power, specialized equipment, safety systems and mechanical infrastructure. As occupiers become more deliberate about their footprints, those differences become harder to overlook.
Owners therefore have more reason to understand where their buildings fit within the available inventory, while brokers need a detailed understanding of how an occupier actually conducts its research and how those requirements could change during the lease.
Demand Is Becoming More Closely Tied to Real Scientific Activity
Slower real estate expansion should not necessarily be confused with a contraction in the underlying life sciences industry.
NIH allocated more than $26.5 billion to research project grants during fiscal 2025, and its overall investment in biomedical research increased from the previous year. FDA approvals provide another measure of activity moving through the development pipeline. The agency approved 46 novel drugs in 2025, only slightly below the 50 approved in both 2024 and 2021.
Employment also offers some perspective on the sector’s scale. Bureau of Labor Statistics data showed approximately 643,000 production and nonsupervisory employees working in physical, engineering and life sciences R&D at the end of 2025.
Those indicators do not guarantee demand for a particular building or market. They do show why vacancy and near-term leasing tell only part of the story. Research continues to receive significant public and private funding, and new therapies continue to reach the market. The connection between that activity and square footage has simply become less automatic.
More Sustainable in Future Cycles
The adjustment may ultimately prove healthy for the sector.
During the earlier expansion, abundant capital, ambitious tenant growth projections and new development reinforced one another. Today’s environment puts more pressure on proposed projects to demonstrate that tenant demand exists before additional space is delivered.
It also makes the differences between markets and buildings more consequential. Established clusters with deep pools of scientific talent, universities, hospitals, venture capital and pharmaceutical companies have advantages that are difficult to reproduce by constructing laboratory buildings alone. Within those clusters, buildings that can accommodate changing research requirements should have an advantage over inventory designed around assumptions that may no longer hold.
For brokers and clients, the questions are becoming more specific. Investors need to understand the depth of the scientific ecosystem surrounding an asset, not simply the amount of laboratory inventory in the market. Owners need to know which improvements will make their properties useful to today’s occupiers. Tenants have an opportunity to be more precise about the space they take and the flexibility they negotiate into their leases.

